Aptevo Therapeutics Announces Poster Presentation at the 64th American Society of Hematology Annual Meeting and ExpositionAccesswire • 11/03/22
Aptevo Therapeutics Reports Second Quarter 2022 Financial Results and Business HighlightsAccesswire • 08/11/22
Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid LeukemiaAccesswire • 06/09/22
Aptevo Therapeutics Reports First Quarter 2022 Financial Results and Business HighlightsAccesswire • 05/12/22
APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual MeetingAccesswire • 04/12/22
Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid LeukemiaAccesswire • 03/29/22
Aptevo Therapeutics Earns $10 Million Non-Dilutive Milestone Payment on Sales of RUXIENCE, Provides Company UpdateAccesswire • 02/09/22
Aptevo Therapeutics' Board Chairman, Fuad El-Hibri, Announces Retirement, Effective April 1, 2022Accesswire • 01/21/22
Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal Nature CommunicationPRNewsWire • 12/15/21
Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal, "Nature Communication"Accesswire • 12/15/21
Aptevo Stock Rallies After Posting First Complete Remission In Early Acute Myeloid Leukemia TrialBenzinga • 11/23/21
Aptevo Therapeutics Reports First Complete Remission, Providing Clinical Update for Its Phase 1b Multi Center, Multi Cohort Expansion Trial in the Treatment of Acute Myeloid LeukemiaAccesswire • 11/23/21
Aptevo Therapeutics Announces the Presentation of Two Abstracts at the Upcoming American Society of Hematology Annual MeetingAccesswire • 11/15/21
Aptevo Therapeutics Reports Third Quarter Financial Results With Business HighlightsAccesswire • 11/12/21
Alligator Bioscience and Aptevo Therapeutics Announce a Poster Presentation of ALG.APV-527 at SITC Annual Meeting 2021Accesswire • 11/11/21
Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cancer Annual MeetingAccesswire • 11/11/21
Aptevo Therapeutics Presents Promising Clinical Data on Its Lead Leukemia Drug Candidate APVO436 at The Second Virtual Conference on Controversies in Leukemias, Euroleuk2021Accesswire • 10/27/21
Aptevo Therapeutics Reports in the Refereed Medical Journal Cancers That the Risk of Cytokine Release Syndrome Is Low for Blood Cancer Patients Treated With Its Bispecific Antibody APVO436Accesswire • 10/26/21
Aptevo Therapeutics Announces Publication of a Scientific Article in Peer-Reviewed Journal, Frontiers in AgingAccesswire • 09/28/21
Aptevo Therapeutics Announces APVO436 Monotherapy is Active in Patients Who Have Relapsed Acute Myeloid Leukemia or Myelodysplastic SyndromeAccesswire • 08/17/21